These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24606688)

  • 21. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
    Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
    J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
    Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
    J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
    Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
    J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NHERF1 regulates gp120-induced internalization and signaling by CCR5, and HIV-1 production.
    Kuang YQ; Pang W; Zheng YT; Dupré DJ
    Eur J Immunol; 2012 Feb; 42(2):299-310. PubMed ID: 22028271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence, dominance, and possible decline of CXCR4 chemokine receptor usage during the course of HIV infection.
    Meehan CJ; Hedge JA; Robertson DL; McCormack GP; Travers SA
    J Med Virol; 2010 Dec; 82(12):2004-12. PubMed ID: 20981786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.
    Mefford ME; Kunstman K; Wolinsky SM; Gabuzda D
    Virology; 2015 Jul; 481():210-22. PubMed ID: 25797607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
    Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
    Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors.
    Hu Q; Huang X; Shattock RJ
    J Gen Virol; 2010 Dec; 91(Pt 12):2965-73. PubMed ID: 20810746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.
    Farzan M; Choe H; Vaca L; Martin K; Sun Y; Desjardins E; Ruffing N; Wu L; Wyatt R; Gerard N; Gerard C; Sodroski J
    J Virol; 1998 Feb; 72(2):1160-4. PubMed ID: 9445013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets.
    Flynn JK; Paukovics G; Moore MS; Ellett A; Gray LR; Duncan R; Salimi H; Jubb B; Westby M; Purcell DF; Lewin SR; Lee B; Churchill MJ; Gorry PR; Roche M
    Virology; 2013 Jul; 442(1):51-8. PubMed ID: 23602007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.
    Agrawal L; VanHorn-Ali Z; Berger EA; Alkhatib G
    Blood; 2004 Feb; 103(4):1211-7. PubMed ID: 14576050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
    Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
    J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short communication: severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions.
    Seclén E; Soriano V; del Mar González M; González-Lahoz J; Poveda E
    AIDS Res Hum Retroviruses; 2011 Sep; 27(9):965-7. PubMed ID: 21314481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779.
    Gharu L; Ringe R; Bhattacharya J
    Virus Res; 2011 Jun; 158(1-2):216-24. PubMed ID: 21524671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Novel Role for the Receptor of the Complement Cleavage Fragment C5a, C5aR1, in CCR5-Mediated Entry of HIV into Macrophages.
    Moreno-Fernandez ME; Aliberti J; Groeneweg S; Köhl J; Chougnet CA
    AIDS Res Hum Retroviruses; 2016 Apr; 32(4):399-408. PubMed ID: 26537334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of fusion protein FLSC IgG1 to CCR5 is enhanced by CCR5 antagonist Maraviroc.
    Latinovic O; Schneider K; Szmacinski H; Lakowicz JR; Heredia A; Redfield RR
    Antiviral Res; 2014 Dec; 112():80-90. PubMed ID: 25453341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
    Peters PJ; Duenas-Decamp MJ; Sullivan WM; Brown R; Ankghuambom C; Luzuriaga K; Robinson J; Burton DR; Bell J; Simmonds P; Ball J; Clapham PR
    Retrovirology; 2008 Jan; 5():5. PubMed ID: 18205925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.